Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial

Research output: Contribution to journalJournal articlepeer-review

Standard

Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial. / Silvestre, Marta P; Fogelholm, Mikael; Alves, Marta; Papoila, Ana; Adam, Tanja; Liu, Amy; Brand-Miller, Jennie; Martinez, J Alfredo; Westerterp-Plantenga, Margriet; Handjieva-Darlenska, Teodora; Macdonald, Ian A; Zhu, Ruixin; Jalo, Elli; Muirhead, Roslyn; Carretero, Santiago Navas; Handjiev, Svetoslav; Taylor, Moira A; Raben, Anne; Poppitt, Sally D.

In: Clinical Nutrition, Vol. 42, No. 5, 2023, p. 636-643.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Silvestre, MP, Fogelholm, M, Alves, M, Papoila, A, Adam, T, Liu, A, Brand-Miller, J, Martinez, JA, Westerterp-Plantenga, M, Handjieva-Darlenska, T, Macdonald, IA, Zhu, R, Jalo, E, Muirhead, R, Carretero, SN, Handjiev, S, Taylor, MA, Raben, A & Poppitt, SD 2023, 'Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial', Clinical Nutrition, vol. 42, no. 5, pp. 636-643. https://doi.org/10.1016/j.clnu.2023.02.023

APA

Silvestre, M. P., Fogelholm, M., Alves, M., Papoila, A., Adam, T., Liu, A., Brand-Miller, J., Martinez, J. A., Westerterp-Plantenga, M., Handjieva-Darlenska, T., Macdonald, I. A., Zhu, R., Jalo, E., Muirhead, R., Carretero, S. N., Handjiev, S., Taylor, M. A., Raben, A., & Poppitt, S. D. (2023). Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial. Clinical Nutrition, 42(5), 636-643. https://doi.org/10.1016/j.clnu.2023.02.023

Vancouver

Silvestre MP, Fogelholm M, Alves M, Papoila A, Adam T, Liu A et al. Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial. Clinical Nutrition. 2023;42(5):636-643. https://doi.org/10.1016/j.clnu.2023.02.023

Author

Silvestre, Marta P ; Fogelholm, Mikael ; Alves, Marta ; Papoila, Ana ; Adam, Tanja ; Liu, Amy ; Brand-Miller, Jennie ; Martinez, J Alfredo ; Westerterp-Plantenga, Margriet ; Handjieva-Darlenska, Teodora ; Macdonald, Ian A ; Zhu, Ruixin ; Jalo, Elli ; Muirhead, Roslyn ; Carretero, Santiago Navas ; Handjiev, Svetoslav ; Taylor, Moira A ; Raben, Anne ; Poppitt, Sally D. / Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial. In: Clinical Nutrition. 2023 ; Vol. 42, No. 5. pp. 636-643.

Bibtex

@article{6e269b1bf48f478aa969560111546098,
title = "Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial",
abstract = "Aims: To examine the differences between HbA1c and glucose related variables in predicting weight loss and glycaemic changes following 8 weeks of low energy diet (LED) in individuals with overweight and hyperglycaemia.Research design and methods: 2178 individuals with ADA-defined pre-diabetes - impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) - who started an 8 week LED weight loss diet, were included in this analysis. Participants were enrolled in the PREVIEW (PREVention of diabetes through lifestyle interventions and population studies In Europe and around the World) clinical trial. Multivariable linear mixed effects regression models and generalised additive mixed effect logistic models were used.Results: Only 1 in 3 participants (33%) had HbA1c levels defined as pre-diabetes. Neither baseline HbA1c, IFG or IGT were associated with body weight change at 8 weeks. Higher baseline body weight, baseline fasting insulin and weight loss predicted normalisation of fasting plasma glucose (FPG), whilst higher baseline fasting insulin, C-reactive protein (hsCRP) and older age predicted normalisation of HbA1c. Additionally, male sex and higher baseline BMI, body fat and energy intake were positively associated with weight loss, whereas greater age and higher HDL-cholesterol predicted less weight loss.Conclusions: Whilst neither HbA1c nor fasting glucose predicts short-term weight loss success, both may impact the metabolic response to rapid weight loss. We propose a role of inflammation versus total body adiposity since these variables are independent predictors of the normalisation of HbA1c and fasting glucose, respectively.",
keywords = "Faculty of Science, Impaired fasting glucose, Impaired glucose tolerance, Hemoglobin A1c, Prediabetes, Weight loss / reduction",
author = "Silvestre, {Marta P} and Mikael Fogelholm and Marta Alves and Ana Papoila and Tanja Adam and Amy Liu and Jennie Brand-Miller and Martinez, {J Alfredo} and Margriet Westerterp-Plantenga and Teodora Handjieva-Darlenska and Macdonald, {Ian A} and Ruixin Zhu and Elli Jalo and Roslyn Muirhead and Carretero, {Santiago Navas} and Svetoslav Handjiev and Taylor, {Moira A} and Anne Raben and Poppitt, {Sally D}",
note = "CURIS 2023 NEXS 077 (In Progress / May 2023) Copyright {\textcopyright} 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.",
year = "2023",
doi = "10.1016/j.clnu.2023.02.023",
language = "English",
volume = "42",
pages = "636--643",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial

AU - Silvestre, Marta P

AU - Fogelholm, Mikael

AU - Alves, Marta

AU - Papoila, Ana

AU - Adam, Tanja

AU - Liu, Amy

AU - Brand-Miller, Jennie

AU - Martinez, J Alfredo

AU - Westerterp-Plantenga, Margriet

AU - Handjieva-Darlenska, Teodora

AU - Macdonald, Ian A

AU - Zhu, Ruixin

AU - Jalo, Elli

AU - Muirhead, Roslyn

AU - Carretero, Santiago Navas

AU - Handjiev, Svetoslav

AU - Taylor, Moira A

AU - Raben, Anne

AU - Poppitt, Sally D

N1 - CURIS 2023 NEXS 077 (In Progress / May 2023) Copyright © 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

PY - 2023

Y1 - 2023

N2 - Aims: To examine the differences between HbA1c and glucose related variables in predicting weight loss and glycaemic changes following 8 weeks of low energy diet (LED) in individuals with overweight and hyperglycaemia.Research design and methods: 2178 individuals with ADA-defined pre-diabetes - impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) - who started an 8 week LED weight loss diet, were included in this analysis. Participants were enrolled in the PREVIEW (PREVention of diabetes through lifestyle interventions and population studies In Europe and around the World) clinical trial. Multivariable linear mixed effects regression models and generalised additive mixed effect logistic models were used.Results: Only 1 in 3 participants (33%) had HbA1c levels defined as pre-diabetes. Neither baseline HbA1c, IFG or IGT were associated with body weight change at 8 weeks. Higher baseline body weight, baseline fasting insulin and weight loss predicted normalisation of fasting plasma glucose (FPG), whilst higher baseline fasting insulin, C-reactive protein (hsCRP) and older age predicted normalisation of HbA1c. Additionally, male sex and higher baseline BMI, body fat and energy intake were positively associated with weight loss, whereas greater age and higher HDL-cholesterol predicted less weight loss.Conclusions: Whilst neither HbA1c nor fasting glucose predicts short-term weight loss success, both may impact the metabolic response to rapid weight loss. We propose a role of inflammation versus total body adiposity since these variables are independent predictors of the normalisation of HbA1c and fasting glucose, respectively.

AB - Aims: To examine the differences between HbA1c and glucose related variables in predicting weight loss and glycaemic changes following 8 weeks of low energy diet (LED) in individuals with overweight and hyperglycaemia.Research design and methods: 2178 individuals with ADA-defined pre-diabetes - impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) - who started an 8 week LED weight loss diet, were included in this analysis. Participants were enrolled in the PREVIEW (PREVention of diabetes through lifestyle interventions and population studies In Europe and around the World) clinical trial. Multivariable linear mixed effects regression models and generalised additive mixed effect logistic models were used.Results: Only 1 in 3 participants (33%) had HbA1c levels defined as pre-diabetes. Neither baseline HbA1c, IFG or IGT were associated with body weight change at 8 weeks. Higher baseline body weight, baseline fasting insulin and weight loss predicted normalisation of fasting plasma glucose (FPG), whilst higher baseline fasting insulin, C-reactive protein (hsCRP) and older age predicted normalisation of HbA1c. Additionally, male sex and higher baseline BMI, body fat and energy intake were positively associated with weight loss, whereas greater age and higher HDL-cholesterol predicted less weight loss.Conclusions: Whilst neither HbA1c nor fasting glucose predicts short-term weight loss success, both may impact the metabolic response to rapid weight loss. We propose a role of inflammation versus total body adiposity since these variables are independent predictors of the normalisation of HbA1c and fasting glucose, respectively.

KW - Faculty of Science

KW - Impaired fasting glucose

KW - Impaired glucose tolerance

KW - Hemoglobin A1c

KW - Prediabetes

KW - Weight loss / reduction

U2 - 10.1016/j.clnu.2023.02.023

DO - 10.1016/j.clnu.2023.02.023

M3 - Journal article

C2 - 36933350

VL - 42

SP - 636

EP - 643

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 5

ER -

ID: 339727961